原发性血小板增多症的三A+(AAA+)生存预测模型:涉及7308例患者的分析
研究基于Mayo Clinic 658例原发性血小板增多症(ET)发现队列,构建整合年龄、中性粒细胞绝对计数、淋巴细胞绝对计数、单核细胞绝对计数、性别、高血压和动脉血栓的AAA+评分,将患者分为超低、低、中、高4个风险组,并在以色列5968例和意大利682例外部队列中验证,其20/25年预测性能优于AAA和IPSET。
要点
- AAA+评分纳入年龄、ANC、ALC、AMC、性别、高血压和动脉血栓,按HR加权计分。
- 4层风险分组:超低0-1分、低2-4分、中5分、高6-14分,中位生存分别为42.7、23、17.3、10.8年。
- 20/25年时间依赖AUC:AAA+ 0.92/0.91,优于AAA 0.86/0.86和IPSET 0.81/0.84。
核心结论
- AAA+评分基于全血细胞计数衍生参数和宿主相关因素,对ET患者生存的预测性能优于IPSET和AAA。
- 研究强调宿主相关因素是ET患者长寿的主要决定因素。
研究设计与样本
- Mayo Clinic发现队列纳入658例ET患者,用于识别AAA独立风险变量并构建AAA+评分。
- 外部队列来自以色列(N=5968)和意大利(N=682)用于验证AAA+风险模型。
主要发现
- 多变量分析HR(95%CI):年龄>70岁15.7(8.4-29.5,8分);年龄50至70岁4.2(2.3-7.5,2分);ANC≥8×10^9/L 1.8(1.2-2.5,1分);ALC<1.7×10^9/L 1.4(1.03-1.9,1分);AMC≥0.5×10^9/L 1.8(1.2-2.6,1分);男性1.8(1.2-2.3,1分);动脉高血压1.8(1.3-2.4,1分);动脉血栓1.6(1.2-2.3,1分)。
- 风险分组:超低0-1分(N=94,中位生存42.7年)、低2-4分(N=297,23年)、中5分(N=66,17.3年)、高6-14分(N=201,10.8年)。
- 20/25年时间依赖预测性能:AAA+ AUC 0.92/0.91,AAA 0.86/0.86,IPSET 0.81/0.84。
- 以色列队列中,将观察生存与年龄和性别匹配的参考人群比较评估疾病特异性死亡率,提示超低风险患者预期寿命接近正常。
关键数值与推荐
- AAA+评分总分0-14分,风险分层:超低0-1分、低2-4分、中5分、高6-14分。
- 计分规则:年龄>70岁8分;年龄50至70岁2分;ANC≥8×10^9/L 1分;ALC<1.7×10^9/L 1分;AMC≥0.5×10^9/L 1分;男性1分;动脉高血压1分;动脉血栓1分。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Survival prediction models in essential thrombocythemia (ET) include the International Prognostic Scoring System (IPSET) and the more recently introduced triple-A (AAA) prognostic score. The latter enlists age and absolute neutrophil (ANC) and lymphocyte (ALC) counts as risk variables. In the current study, a Mayo Clinic discovery cohort of 658 patients with ET was used to identify AAA-independent risk variables. Accordingly, multivariable analysis-derived HRs (95% CI) were 15.7 (8.4-29.5) for age > 70 years (8 points); 4.2 (2.3-7.5) for age 50 to 70 years (2 points); 1.8 (1.2-2.5) for ANC ≥ 8 × 109/L (1 point); 1.4 (1.03-1.9) for ALC < 1.7 × 109/L (1 point); 1.8 (1.2-2.6) for absolute monocyte count (AMC) ≥ 0.5 × 109/L (1 point); 1.8 (1.2-2.3) for male sex (1 point); 1.8 (1.3-2.4) for arterial hypertension (1 point); and 1.6 (1.2-2.3) for arterial thrombosis (1 point). HR-weighted scoring enabled a 4-tiered risk classification: ultra-low (0-1 points; N = 94; median survival 42.7 years), low (2-4 points; N = 297; 23 years), intermediate (5 points; N = 66; 17.3 years), and high (6-14 points; N = 201; 10.8 years). Time-dependent predictive performance at 20/25 years favored AAA+ (AUC 0.92/0.91) vs. AAA (0.86/0.86) vs. IPSET (0.81/0.84). The AAA+ risk model was subsequently validated by two external cohorts from Israel (N = 5968) and Italy (N = 682). In the cohort from Israel, disease-specific mortality was assessed by comparing observed survival to an age- and sex-matched reference population, which suggested near-normal life expectancy in ultra-low risk patients. The current study highlights host-related factors as the primary determinants of longevity in ET and provides a composite risk score (AAA+) that is based on complete blood count-derived parameters and host-related factors. Predictive performance of the new model was shown to be superior to that of IPSET and AAA.
引用
- Tefferi A, Loscocco GG, Rokach L, et al. Triple A Plus (AAA +) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients. Am J Hematol. 2025. PMID: 40899793. doi:10.1002/ajh.70065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。